Jae H. Park, MD

The hematologic oncologist from Memorial Sloan Kettering Cancer Center discussed emerging CAR T-cell therapies in hematologic malignancies.

Jae H.Park, MD, discusses potential alternate CAR T-cell targets in B-cell malignancies.

Jae H. Park, MD, discusses encouraging data with CAR T-cell therapy in acute lymphoblastic leukemia.

Jae H. Park, MD, attending physician, Leukemia Service and Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the use of CAR T cells in the treatment of patients with acute lymphoblastic leukemia.

Jae H. Park, MD, discusses a particular challenge he sees in using CAR T-cell therapies in patients with acute myeloid leukemia.